# Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

> **NCT05410847** · PHASE2 · UNKNOWN · sponsor: **Hebei Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Camrelizumab Nab-Paclitaxel S-1

## Key facts

- **NCT ID:** NCT05410847
- **Lead sponsor:** Hebei Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-30
- **Primary completion:** 2023-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05410847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05410847, "Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05410847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*